Company Profile
uniQure N.V. Stock Price, News & Analysis
- Ticker:
- QURE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands
Stock performance
45.36 USD (+2.53%)
Close
Last updated: August 6, 2026
1.69B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, QURE closed up 2.53% at $45.36. No new same-company headline was identified in the current news window.
Company overview
Business overview
uniQure is a gene-therapy company focused on rare diseases and neurological disorders. Its platform and clinical programs make it one of the better-known names in viral-vector gene therapy.
Geographic Base and Sector Classification
Headquartered in the Netherlands and listed on NASDAQ as an ADR, uniQure has a global gene-therapy footprint.
Business Model Characteristics
The business is driven by clinical data, manufacturing capability, and the challenge of turning gene therapy into durable value.
Position Within the Biotechnology Landscape
uniQure is a classic gene-therapy catalyst name whose valuation is highly sensitive to program and safety outcomes.
Future catalysts
uniQure's catalysts are AMT-130 in Huntington's disease and the rest of its gene-therapy pipeline, where any clean clinical or regulatory step can matter a lot. The company still needs the next update to show the gene-therapy platform can keep building beyond a single program.
Recent news
- 01
- 02
- 03
- 04
uniQure Announces Company Presentations at Upcoming May Conferences
Source: uniQure N.V.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of uniQure N.V. (QURE)?
uniQure N.V. (QURE) most recently closed at 45.36 USD, a +2.53% move versus the previous session.
What is the market cap of uniQure N.V. (QURE)?
uniQure N.V. currently has a market capitalization of 1.69B USD on BioPharmSignal.
What does uniQure N.V. do?
uniQure is a gene-therapy company focused on rare diseases and neurological disorders. Its platform and clinical programs make it one of the better-known names in viral-vector gene therapy.
On which exchange is QURE stock listed?
uniQure N.V. (QURE) is associated with NASDAQ, Netherlands, Biopharma.
What is AMT-130?
uniQure's catalysts are AMT-130 in Huntington's disease and the rest of its gene-therapy pipeline, where any clean clinical or regulatory step can matter a lot.
Which conditions is uniQure N.V. targeting with AMT-130?
uniQure N.V. is associated with rare disease based on its company overview and current catalyst commentary.
How does uniQure N.V. describe recent progress with AMT-130?
uniQure's catalysts are AMT-130 in Huntington's disease and the rest of its gene-therapy pipeline, where any clean clinical or regulatory step can matter a lot.
What is Huntington?
uniQure's catalysts are AMT-130 in Huntington's disease and the rest of its gene-therapy pipeline, where any clean clinical or regulatory step can matter a lot.